Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology

    Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer
             microRNA Diagnostic Manuscript by Molecular Oncology

Unedited manuscript now available online

PR Newswire

PHILADELPHIA and REHOVOT, Israel, April 1, 2013

PHILADELPHIAand REHOVOT, Israel, April 1, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces that a manuscript regarding
the development and validation of the Company's microRNA-based diagnostic
assay for the classification of renal cell tumors has been accepted for
publication by Molecular Oncology. Yael Spector, a scientist from Rosetta
Genomics, and Dr. Eddie Fridman, a pathologist and an expert in urological
pathology from Sheba Medical Center in Tel-Hashomer, Israel, are the lead
authors on the manuscript.

An unedited version of the manuscript is available online ahead of print
publication of the final article at
http://www.sciencedirect.com/science/article/pii/S157478911300046X.

The manuscript discusses the development and validation of the miRview^®
kidney assay, which differentiates between the four main types of primary
kidney tumors: the three subtypes of renal cell carcinoma (RCC) namely clear
cell, papillary and chromophobe RCC, and typically benign behaving oncocytoma.
The assay was developed on a microarray platform using 181 training samples
and validated on an independent set of 201 samples. The assay provided results
for 92% of the validation samples, with 95% accuracy.

The topic of this manuscript will also be summarized in a poster to be
presented on April 7 at the American Association for Cancer Research (AACR)
Annual Meeting 2013 in Washington, D.C.

"There are an estimated 65,000 new cases of kidney cancer each year in the
U.S. and more than 13,000 deaths. Distinguishing between the four main types
of primary kidney tumors is critical in determining the optimal treatment
regimen," said Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics. "Our miRview^® kidney assay accurately classifies clear
cell RCC, papillary RCC, chromophobe RCC and oncocytoma. We are delighted that
this work has been accepted for publication in Molecular Oncology, an
important industry trade journal."

"The classification into subtypes of RCC has historically been less than
definitive by histology, cytology and immunohistochemistry particularly in the
growing context of fine needle aspirate (FNA) diagnostic specimens. The
discrimination of the four subtypes can lead to the avoidance of aggressive
surgical intervention in oncocytomas, and the others have differing biological
behaviors that can be correlated with subtype. Importantly, newer therapeutic
agents may show evidence of specificity of response by cell type. The expanded
clarity of RCC diagnosis through the availability of this test will help lead
to improved rationalization and optimization of new and emerging therapies,
particularly in the community setting," said Bob Wassman, M.D., Chief Medical
Officer of Rosetta Genomics.

About miRview^® Testing Services
miRview^® assays are a series of microRNA-based diagnostic testing services
offered by Rosetta Genomics. miRview^® mets² accurately identifies the primary
tumor type in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). miRview^® meso diagnoses mesothelioma, a cancer
connected to asbestos exposure. miRview^® lung accurately identifies the four
main subtypes of lung cancer using small amounts of tumor cells. miRview^®
kidney accurately classifies the four most common kidney tumors: clear cell
renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
miRview^® assays are designed to provide objective diagnostic data; it is the
treating physician's responsibility to diagnose and administer the appropriate
treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000
patients a year may benefit from the miRview^® mets² test assay, 60,000 from
miRview^® meso, 65,000 from miRview^® kidney and 226,000 patients from
miRview^® lung. The Company's assays are offered directly by Rosetta Genomics
in the U.S., and through distributors around the world. For more information,
please visit www.mirviewdx.com. Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta'sstrategic plan,Rosetta's development or commercialization of
molecular diagnostics or therapeutics, the market acceptance of Rosetta's
miRview^®assays,particularly miRview^®mets^2, Rosetta's capitalization of
its microRNA platform, Rosetta's patent positionand Rosetta's development of
personalized medicine productsand services constitute forward-looking
statements for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a result of
various important factors, including those risks more fully discussed in the
"Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year
ended December 31, 2012as filed with the SEC. In addition, any
forward-looking statements represent Rosetta's views only as of the date of
this release and should not be relied upon as representing its views as of any
subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

or

Bruce Voss
(310) 691-7100
bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.

Website: http://www.mirviewdx.com
 
Press spacebar to pause and continue. Press esc to stop.